Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com -- AnaptysBio Inc (NASDAQ:ANAB) stock rose 4.4% on Wednesday after the clinical-stage biotech company announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis patients.
The company reported that the drug, described as a "selective and potent pathogenic T cell depleter," showed deepening clinical responses from Week 12 to Week 28 across multiple efficacy measures, regardless of patients’ prior treatment history. Importantly, these benefits remained durable for at least three months after treatment ended.
The 424-patient global trial demonstrated that rosnilimab was well-tolerated through the 38-week study period, with no treatment-related serious adverse events and no malignancies reported in treated patients.
Data presented at the American College of Rheumatology Convergence 2025 in Chicago showed that by Week 28, measures including Clinical Disease Activity Index (CDAI) low disease activity, CDAI remission, and ACR50/70 response rates continued to improve across all patient groups, including those previously treated with anti-TNFα, anti-IL6R, or JAK inhibitors.
The drug demonstrated particularly strong results in patients who had previously tried at least two prior biologic or targeted synthetic disease-modifying antirheumatic drugs, especially at the mid (400mg Q4W) and high (600mg Q2W) doses.
From a mechanistic perspective, rosnilimab reduced T peripheral helper (Tph) cells by more than 90% in the periphery for all doses by Week 6, with significant reductions also observed in T cell and B cell activation in synovial biopsies.
The positive data supports AnaptysBio’s development of rosnilimab as a potential new treatment option for rheumatoid arthritis patients, particularly those who have cycled through multiple existing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.